We are entering an era of medicine where increasingly sophisticated data will be obtained
from patients to determine proper diagnosis, predict outcomes and direct therapies. We …

RAS and MYC rank amongst the most commonly altered oncogenes in cancer, with RAS
being the most frequently mutated and MYC the most amplified. The cooperative interplay …

Cancer is highly infiltrated by myeloid-derived suppressor cells (MDSCs). Currently
available immunotherapies do not completely eradicate MDSCs. Through a genome-wide …

It is well established that mutations in the canonical WNT-signalling pathway play a major
role in various cancers. Critical to developing new therapeutic strategies is understanding …

Cancer stem cells (CSCs) are a type of stem cell that possesses not only the intrinsic
abilities of stem cells but also the properties of cancer cells. Therefore, CSCs are known to …

The therapeutic benefits of immune checkpoint inhibitors (ICIs), which enable antitumor
immune responses, can be tempered by unwanted immune-related adverse events (irAEs) …

MYC is a proto-oncogene that encodes a powerful regulator of transcription and cellular
programs essential for normal development, as well as the growth and survival of various …

The roles of oncogenic KRAS in tumor immune evasion remain poorly understood. Here,
mutant KRAS is identified as a key driver of tumor immune evasion in colorectal cancer …

Glioblastoma multiforme is one of the calamitous primary glial brain tumors with extensive
heterogeneity at cellular and molecular levels. While maximal surgical resection trailed by …

The c-Myc signaling is a new emerging target in cancer therapy. Activation of c-Myc
signaling leads to cancer growth and invasion in vitro and in vivo. The stability of c-Myc can …